FDA Approves Isembyld for SMA
FDA approved Isembyld (apitegromab-mstn) for adults and children two years and older with spinal muscular atrophy who are already receiving an SMN2-targeted treatment. The approval establishes the first U.S. therapy for SMA directed at…
